Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property

DiagnosTear Signs Letter of Intent to Advance Commercial Expansion of TeaRx(TM) in India

By The Northwire Desk — AI Analysis Jan 22, 2026 · 17:01 DTR · 0.55 DiagnosTear Technologies Inc.
DTR · Price

Executive Summary

  • DiagnosTear Technologies Inc. signed a non‑binding Letter of Intent with Renovate Biologicals Pvt. Ltd. to evaluate and potentially distribute its CE‑IVD approved dry‑eye diagnostic test, TeaRx™, in India through April 30 2026.
  • The LOI grants Renovate exclusive market‑facing rights for the evaluation period and sets a target to negotiate a definitive commercial agreement by June 1 2026.
  • This partnership expands DiagnosTear’s commercialization footprint into one of the world’s largest ophthalmic markets, supporting its global rollout strategy for TeaRx™.

Key Details

  • Parties: DiagnosTear Technologies Inc. (CSE: DTR) and Renovate Biologicals Pvt. Ltd., a Hyderabad‑based ophthalmic distribution company.
  • Product Covered: TeaRx™ – a CE‑IVD approved rapid point‑of‑care test for dry eye disease using tear‑fluid analysis.
  • LOI Scope:
  • Renovate will exclusively lead market‑facing activities (engagement with ophthalmologists, clinics, KOLs) in India during the LOI Period (until 30 April 2026).
  • Activities include assessing commercial demand, adoption potential, pricing structure, distribution strategy, and long‑term collaboration models.
  • Milestones: Parties aim to reach a definitive commercial agreement by 1 June 2026 following the evaluation period.
  • Strategic Rationale: India represents a large, fast‑growing ophthalmic market; the partnership is intended to accelerate TeaRx™’s entry and scale in the region.
  • Management Quote: “India is a strategically important market for DiagnosTear… This LOI reflects our continued effort toward building a strong international distribution network and accelerating the commercial rollout of TeaRx™ globally,” said Dr. Shimon Gross, CEO.

Notable Quotes

“India is a strategically important market for DiagnosTear, with a large patient population and growing demand for efficient, point‑of‑care diagnostic solutions,” – Dr. Shimon Gross, CEO, DiagnosTear Technologies Inc.

Read the original news release →

More from DiagnosTear Technologies Inc.

Jun 05, 2026 · 08:31

DiagnosTear’s TeaRx Validation Fails to Halt 65% Decline as CLARIFY Royalties Weigh on Near-Term Upside

Other May 12, 2026 · 16:06

DiagnosTear Solidifies CLARIFY License, Moving from Dry-Eye to Blood Diagnostics, but Commercialization Cliff Looms

Other Feb 26, 2026 · 17:01

DiagnosTear Announces Regulatory Approvals in France and Study Initiation with AlyaTec for TeaRx(TM) Red Eye

Regulatory Feb 20, 2026 · 17:01

DiagnosTear Advances UK Market Entry Through Commercial Collaboration with Hanson Medical

M&A / Property Dec 17, 2025 · 18:01

DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count

Other Dec 02, 2025 · 17:01

DiagnosTear Announces Clinical Study with AlyaTec to Advance Analytical Validation and FDA Submission Pathway of TeaRx(TM) Red Eye Diagnostic Test

Other